Akeso Inc
HKEX:9926

Watchlist Manager
Akeso Inc Logo
Akeso Inc
HKEX:9926
Watchlist
Price: 120.4 HKD 2.82% Market Closed
Market Cap: 110.9B HKD

Akeso Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Akeso Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Akeso Inc
HKEX:9926
Cash from Operating Activities
-ÂĄ527.6m
CAGR 3-Years
19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Operating Activities
-ÂĄ1.3B
CAGR 3-Years
47%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash from Operating Activities
ÂĄ1.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
3SBio Inc
HKEX:1530
Cash from Operating Activities
ÂĄ3.1B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Operating Activities
ÂĄ355.1m
CAGR 3-Years
-40%
CAGR 5-Years
5%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Cash from Operating Activities
-ÂĄ429.8m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Akeso Inc
Glance View

Market Cap
108.1B HKD
Industry
Biotechnology

In the bustling landscape of biotechnology, Akeso Inc. emerges as a dynamic force addressing the dynamic and often daunting challenges of the medical world. Founded in 2012 and headquartered in China, this innovative company has made significant strides in the realm of biopharmaceuticals, particularly focusing on the research and development of novel therapies for oncology and immunology. Akeso Inc. differentiates itself through its comprehensive end-to-end approach, spanning discovery, clinical development, and commercialization. By leveraging its robust pipeline of therapeutic antibodies, the company constantly seeks to pioneer breakthroughs in cancer treatment and autoimmune disorders, thus driving its mission to enhance patient outcomes and address unmet medical needs. The economic engine of Akeso Inc. is driven by its ability to transform scientific research into viable therapeutic products. Revenue generation centers around the commercialization of their proprietary drugs, which often involves collaborations and strategic partnerships with major pharmaceutical players globally. These alliances not only expand the reach of Akeso's innovations but also provide essential capital and shared expertise that accelerate product advancement. The company's business model is further bolstered by licensing agreements and milestone payments, creating a steady stream of income as they navigate the rigorous pathways of drug approval and market entry. Through these ventures, Akeso Inc. not only secures its financial health but also continuously reinvests in its research endeavors, fueling a cycle of innovation that propels it forward in the competitive biotech arena.

Intrinsic Value
127.03 HKD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Akeso Inc's Cash from Operating Activities?
Cash from Operating Activities
-527.6m CNY

Based on the financial report for Dec 31, 2024, Akeso Inc's Cash from Operating Activities amounts to -527.6m CNY.

What is Akeso Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-19%

The average annual Cash from Operating Activities growth rates for Akeso Inc have been 19% over the past three years , -19% over the past five years .

Back to Top